The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to 0.5 mg naloxone HCl dissolved in an application fluid of a volume of 250 μl. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.本發明關於包含給藥單元(dosing unit)之鼻內藥物劑型,該給藥單元包含溶解在體積250微升之施藥流體中的相當於0.5毫克那若松(naloxone)鹽酸鹽之量的那若松或其藥學上可接受之鹽。再者,本發明關於用於治療類鴉片用藥過量和/或至少一種類鴉片用藥過量之症狀的這類鼻內藥物劑型。